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Summary  Worldwide  incidence  of  obesity  is  increasing  and  impaired  outcome
in  postoperative  patients  has  been  described.  Antibiotic  prescribing  is  compli-
cated  by  different  pharmacology  in  this  population.  This  study  evaluates  mortality
and  morbidity  of  obese  postoperative  patients  and  explores  possible  relation  to
antibiotic  therapy.  Therefore,  data  obtained  in  a  prospective  study  in  2009—2010
were  analysed.  Postoperative  patients  on  5  ICUs  were  included  with  >48  h  of
ICU  treatment  and  documented  body-mass-index  (BMI).  Altogether  451  non-obese
patients  (BMI  <  30  kg/m2) were  compared  with  130  obese  patients  including  propen-
sity  score  matching.  There  was  signiﬁcant  heterogeneity  of  baseline  characteristics.
ICU-mortality  was  7.5%  in  non-obese  and  7.7%  in  obese  patients  (p  >  0.999),  but
65.4%  of  obese  patients  required  mechanical  ventilation  compared  with  only  53.2%
of  non-obese  patients  (p  =  0.016).  These  ﬁndings  were  validated  in  multivariate
regression  analyses  (adjusted  OR  for  ICU-mortality  for  obese  patients  0.53,  95%-
CI  0.188—1.321,  p  =  0.197;  adjusted  OR  for  mechanical  ventilation  1.841,  95%-CI
1.113—3.076,  p  =  0.018).  Results  were  conﬁrmed  by  propensity  score  matching.
Therapeutic  drug  monitoring  for  vancomycin  (TDM)  showed  that  underdosing  and
overdosing  occurred  more  often  in  obese  patients  and  sufﬁcient  TDM  levels  were
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less  often  achieved.  In  conclusion,  obesity  is  associated  with  increased  morbidity
but  ICU  mortality  is  equal  compared  with  a non-obese  population.  Pharmacological
in  observed  differences  in  antibiotic  therapy  and  in  obese
specially  of  importance.
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Introduction
In the  intensive  care  unit  (ICU)  obesity  is  a com-
mon comorbidity  in  about  20%  of  patients  and  rising
incidence  is  described  worldwide  [1].  In  concord-
ance with  the  World  Health  Organisation,  obesity
is most  commonly  deﬁned  as  a  body  mass  index
(BMI) of  ≥30  kg/m2 [2,3]. Obesity  is  associated
with increased  morbidity  of  ICU  patients  but  there
remains  uncertainty  regarding  the  effect  on  mor-
tality. Similar  mortality  rates  were  described  by
several authors  comparing  obese  and  non-obese  ICU
patients [4,5].  These  ﬁndings  were  contrasted  by  a
meta-analysis  of  Fezeu  et  al.  [6]  that  described  a
signiﬁcantly  higher  mortality  in  obese  ICU  patients
with H1N1  inﬂuenza  for  death.  A  doubled  mortality
rate was  also  found  in  obese  medical  ICU  patients
admitted due  to  obstructive  airway  disease,  pneu-
monia, and  sepsis  [7]. Similarly,  in  a  cohort  study  of
patients following  trauma  Byrnes  et  al.  described
an increased  mortality  rate  for  obese  patients
[8].  However,  other  authors  described  even  lower
mortality  in  obese  patients  [9]. Potential  mech-
anisms  to  explain  this  variance  are  still  under
debate. There  is  evidence  that  obese  patients  expe-
rience higher  postoperative  pain  intensity  and  are
under higher  risk  to  acquire  postoperative  infec-
tions  [10—12]. Nosocomial  infections  and  especially
pneumonia and  surgical  site  infections  were  found
to occur  more  often  in  obese  patients  [13,14]. A
recent study  by  Ferrada  et  al.  focussing  on  patients
following  emergency  surgery  described  higher  rates
for surgical  site  infections  [15]. Other  authors
reported that  weight-adapted  dosing  strategies
for benzodiazepines  and  opioids  were  one  factor
altering  outcome  [16]. In  this  context,  differ-
ences in  pharmacokinetics  and  pharmacodynamics
in obese  patients  were  described  for  volume  of  dis-
tribution,  changes  in  hepatic  metabolism  and  renal
function that  may  lead  to  antibiotic  overdosing  as
well as  underdosing  [17,18].  Currently,  there  is  a
lack of  evidence  to  guide  an  optimal  dosing  reg-
imen for  antibiotic  agents  [18]. Antibiotic  dosing
is most  commonly  based  on  weight  together  with
renal  or  hepatic  function  and  can  be  adapted  using
results from  therapeutic  drug  monitoring  for  some
P
P
ogents  [19]. In  summary,  obese  patients  seem  to
xperience  increased  morbidity  following  surgery
ut relation  on  overall  outcome  is  not  completely
lear. Furthermore,  there  is  currently  no  conclusive
echanism identiﬁed  that  might  explain  a  poten-
ial protective  effect  on  outcome  [20]. Attention
as been  drawn  to  dosing  of  antiinfective  agents
n obese  ICU  patients  as  one  potential  contributing
actor [18,21]. Against  this  background,  we  con-
ucted this  observational  study  in  postoperative
CU patients.  The  aims  of  this  study  were  to  assess
CU mortality  in  obese  patients  and  to  compare
utcome with  non-obese  patients;  to  describe  peri-
perative  morbidity  and  to  relate  outcome  with
ntibiotic  therapy  including  therapeutic  drug  mon-
toring.
aterial and methods
tudy design and setting
his  study  was  conducted  as  secondary  analysis  of
 prospective  interventional  study  [22]. This  initial
rial was  performed  at  Charité  hospital,  a  ter-
iary university  hospital  in  Berlin,  Germany.  The
tudy evaluates  an  ICU  stewardship  program  of
he ABx  Study  Group  (ISRCTN54598675)  on  infec-
ion management  and  included  all  consecutively
dmitted ICU  patients  [22]. Data  used  for  the
resent analysis  were  obtained  from  August  2009
o April  2010  including  patients  predominantly  fol-
owing surgery  or  major  trauma.  The  study  wards
omprised ﬁve  surgical  ICUs  with  a  focus  on  postop-
rative patients  from  different  surgical  disciplines
neurosurgery,  abdominal  surgery,  cardiac  surgery,
rauma,  gynaecology)  and  patients  with  major
rauma. The  project  was  approved  by  the  local
thics Review  Board  and  the  data  safety  authori-atients and data collection
atients  older  than  18  years  admitted  to  one
f the  ICUs  with  at  least  two  days  of  ICU





































































































fMI  is not  associated  with  increased  ICU  mortality  b
reatment  were  included  into  this  study.  For  analy-
is, patients  were  excluded  when  anthropometric
alues of  weight  and  body  height  were  not  doc-
mented to  calculate  body  mass  index  (BMI).
ll data  were  prospectively  obtained  during  ICU
tay.
eﬁnitions and measurement
besity  classiﬁcation  was  applied  based  on  the  cal-
ulated BMI  with  a  range  of  ≥30  kg/m2 for  obese
atients and  <30  kg/m2 representing  the  non-obese
ontrol population.
The primary  outcome  parameter  was  all  cause
CU mortality.  Secondary,  postoperative  morbidity
f patients  was  focussed  deﬁned  as  requirement
f invasive  mechanical  ventilation  via  any  endotra-
heal  tube;  as  was  diagnosis  of  infections  on  ICU
dmission  or  during  ICU  stay.  Furthermore,  the  trial
ncorporated  assessment  of  quality  of  antibiotic
herapy. Therefore,  antibiotic  treatment  and  infec-
ion diagnostics  were  reviewed  by  infectiological
xperts for  every  ICU  day  of  every  patient.  Indica-
ion of  antibiotic  therapy  was  evaluated  as  well  as
hosen agents  or  combination  therapy  as  described
reviously [22].  Brieﬂy,  for  all  ICU  days  every
pplication of  an  antibiotic  agent  was  assessed.
t was  evaluated,  whether  the  antibiotic  was  pre-
cribed  with  sufﬁcient  evidence  for  an  infection
nd whether  applied  drugs  were  recommended  by
he hospital  antibiotic  guideline  for  this  indication.
ubsequently, reassessment  of  antibiotic  therapy
as evaluated.  De-escalation  of  therapy  is recom-
ended  in  case  of  resolution  of  clinical  signs  of
nfection  to  avoid  unnecessary  prolonged  antibi-
tic exposure.  Every  ICU  day  in  concordance  with
uidelines was  divided  by  all  observed  ICU  days
nd transferred  into  a  relative  measurement  [22].
xemplarily,  for  vancomycin  therapy  an  initial  load-
ng dose  of  1  g  intravenous  drug  is  recommended
ndependent  from  renal  function.  This  loading  dose
s then  followed  by  continuous  infusion  or  followed
y intermittent  administration.  For  continuous  van-
omycin infusion  in  patients  with  normal  renal
unction, 2  g  vancomycin  is  applied  during  24  h
sing a  central  line;  for  intermittent  administra-
ion 500  mg  vancomycin  is  given  every  6 h  or  1  g
ancomycin is  given  every  12  h  with  duration  of
nfusion of  at  least  1 h.  Therapeutic  drug  monitoring
TDM) is  advised  to  be  initiated  after  24  h  of  contin-
ous vancomycin  administration  or  just  before  the
th administration  of  intermittent  vancomycin  infu-
ion. This  dosing  protocol  has  been  implemented  in
he study  wards  and  is  available  as  a  national  stew-
rdship  program  (www.dgai-abx.de).  Vancomycin





opulation  and  therapeutic  drug  monitoring  (TDM)
s established  in  clinical  routine,  we  were  able  to
nclude analyse  of  antibiotic  serum  levels  into  this
tudy. For  this  purpose,  the  subgroup  of  patients
ith vancomycin  therapy  during  ICU  treatment  was
urther explored.  In  these  patients  vancomycin
erum trough  levels  were  evaluated.  Although  opti-
al vancomycin  serum  levels  are  under  debate  in
he ICU  setting,  our  hospital  policy  included  recom-
endations  to  achieve  and  maintain  a serum  level
f 10—20  mg/L  vancomycin.  Consequently,  serum
evels  of  less  than  10  mg/L  vancomycin  were  clas-
iﬁed as  underdosed  and  were  expected  to  be  the
hreshold  for  dosing  changes  with  an increase  of
aily vancomycin  dosage.  Serum  levels  of  more
han 20  mg/L  vancomycin  were  classiﬁed  as  over-
osed and  vancomycin  therapy  had  to  be  adapted
23]. To  further  quantify  underdosing  and  over-
osing,  percentage  of  all  days  with  TDM  results
bove and  below  targeted  trough  serum  levels  of
0—20 mg/L  vancomycin  were  calculated  for  each
atient.
tatistical analysis and ethic review
esults  are  given  depending  on  their  scale  in  pro-
ortions  (%),  median  including  25—75%  quartiles
25|75) or  arithmetic  mean  and  standard  deviation
mean  ±  STD).  As  appropriate,  tests  for statisti-
al signiﬁcance  were  performed  with  two-tailed
tudent’s t-test,  Wilcoxon—Mann—Whitney  test  or
isher’s exact  test.  A  p-value  <0.05  was  considered
o be  statistically  signiﬁcant.  Multivariate  analy-
es of  binary  outcome  parameters  were  realised  by
ogistic regression  and  visualized  by  showing  related
dds ratios  with  95%  conﬁdence  intervals.  For  logis-
ic regression  analysis,  all  covariables  entered  the
odel (age,  female  sex,  SAPS  II  on  admission,  pre-
xisting comorbidities,  surgery,  Infections  on  ICU
nd BMI  group)  and  were  processed  in  a  back-
ard selected  model  with  all  cause  ICU  mortality
r requirement  of  invasive  mechanical  ventila-
ion as  dependent  variable.  These  results  were
acked up  using  the  method  of  Propensity  score
atching as  described  in  [24].  Therefore,  patients
ere matched  according  to  BMI  status  using  the
elected  variables  in  the  logistic  regression  models
o account  for  heterogeneity  of  all  relevant  base-
ine characteristics.  The  resulting  propensity  scores
or patients  were  used  for  1:1  nearest  neighbour
atching and  achieved  balanced  groups  in  regard
o baseline  characteristics  except  for  the  factor  of
besity. All  analyses  were  performed  with  IBM  SPSS
2.0 and  R  3.0.2.
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Table  1  Patients  characteristics.
Variable  Non-obese
N  =  451
Obese  patients
N  =  130
p-Value
BMI  median  (25%|75%  quartiles)  25  (23|27)  34  (31|37)  <0.001
Age  median  (25%|75%  quartiles)  63  (50|72)  64  (53|72)  0.346
Female  sex  N  (%)  193  (43%)  61  (47%)  0.404
SAPS  II  median  (25%|75%  quartiles) 36  (24|48)  35  (25|53)  0.351
Pre-existing  comorbidities  N  (%)
Immune  suppression 35  (8%) 10  (8%) >0.999
Cardiac  236  (52%) 90  (69%) 0.001
Vascular  183  (41%)  67  (52%)  0.027
Pulmonary  103  (23%)  24  (19%)  0.336
Hepatic  48  (11%)  23  (18%)  0.034
Renal  101  (22%)  47  (36%)  0.002
Diabetes  mellitus  155  (34%)  85  (65%)  <0.001
Neurological  109  (24%)  31  (24%)  >0.999
Immunological  17  (3.8%)  6  (4.6%)  0.616
Oncological  122  (27%)  34  (26%)  0.911
Surgical  admission  327  (73%)  100  (77%)  0.367
OP  —  category  N  (%)
Head/neck/extracranial  22  (5%)  6  (5%)  >0.999
Abdomen  88  (20%)  26  (20%)  0.901
Intracranial  70  (16%) 9  (7%)  0.013
Musculoscelettal  40  (9%)  11  (9%)  >0.999
Vascular 5  (1%) 0  (0%)  0.592
Cardial  92  (20%) 43  (33%) 0.003
Pulmonary  4  (1%) 1  (1%) >0.999
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Results
Patients baseline characteristics
Altogether  696  consecutive  ICU  patients  were  pri-
marily screened  for  study  inclusion.  Finally,  581
patients  fulﬁlled  inclusion  criteria  and  had  anthro-
pometric  parameters  documented,  451  with  a
BMI < 30  kg/m2 and  130  with  a  BMI  ≥  30  kg/m2.
Obese patients  presented  signiﬁcantly  more  often
with pre-existing  diabetes  mellitus  and  seque-
lae of  metabolic  syndrome  like  cardiac  or  renal
comorbidity. Consequently,  admissions  following
cardio-surgical procedures  were  more  common  in
this group  (Table  1).
Hospital mortality and morbidity
The  all  cause  ICU  mortality  in  the  population
was 44  out  of  581  patients  (7.6%)  and  distributed
equally between  study  groups,  as  was  length  of
ICU stay.  Obese  patients  required  signiﬁcantly
more often  invasive  ventilation.  In  the  subgroup
of patients  with  invasive  ventilation,  duration




ﬁ3  (1%)  >0.999
Table  2).  Occurrence  of  infections  was  also  dis-
ributed  equally  between  groups  and  especially
neumonia and  infections  of  soft  tissues  did  not
how signiﬁcant  differences  between  obese  and
on-obese  patients.
ntibiotic therapy
uality  of  antibiotic  therapy  did  not  differ  signif-
cantly in  terms  of  overall  adherence  to  locally
dapted guidelines.  In  non-obese  patients  mean
4 ±  32%  ICU  days  were  found  concordant  with
uidelines compared  with  76  ±  32%  in  obese  patient
p =  0.488).
Vancomycin  therapy  was  applied  in  a  subgroup
f 117  patients,  91  non-obese  patients  versus  26
bese patients  (Table  3).  Evaluating  all  therapy
ays, mean  serum  levels  did  not  differ  between
bese and  non-obese  patients.  Further  exploration
f vancomycin  TDM  results  in  this  subgroup  revealed
hat overdosing  and  underdosing  occurred  more
ften in  obese  patients  without  reaching  statisti-
al signiﬁcance  level.  Notably,  when  evaluating  the
rst trough  TDM  level  measured,  signiﬁcantly  less
BMI  is not  associated  with  increased  ICU  mortality  but  morbidity  581
Table  2  Mortality,  morbidity  and  infections  of  patients  during  ICU  stay.
Variable  Non-obese
N  =  451
Obese  patients
N  =  130
p-Value
Mortality  N  (%)  34  (7.5%)  10  (7.7%)  >0.999
ICU  stay  in  days;  median  (25|75%)  6  (4|14)  6  (4|12)  0.833
Mechanical  ventilation  N  (%) 240  (53.2%) 85  (65.4%)  0.016
Duration  of  ventilation  in  daysa median  (25|75%) 3 (1|14) 3  (1|10) 0.374
Infections  on  ICU  in  N  (%)
Pneumonia  153  (34%) 39  (30%) 0.459
Abdominal  43  (10%)  10  (8%)  0.606
Urinary  25  (6%)  8  (6%)  0.830
Bones  and  joints  13  (3%)  5  (5%)  0.569
Endocarditis  12  (3%)  3  (2%)  >0.999
Soft  tissue  21  (5%)  4  (3%)  0.624
Bacteraemia  28  (6%)  14  (11%)  0.085
Infection  with  unknown  focus  17  (4%)  11  (9%)  0.036




































ma For evaluation of duration of ventilation only patients wit
bese  patients  achieved  a  targeted  serum  level  of
0—20 mg/dl  and  consequently  therapy  had  to  be
dapted  (Table  3).
ultivariate analysis for ICU mortality and
orbidity
ll  cause  ICU  mortality  was  evaluated  as  dependent
ariable in  multivariate  logistic  regression  analyses
o account  for  differences  in  patient  characteris-
ics between  study  groups.  All  variables  entered
he regression  model  and  were  processed  in  a
ackward elimination  procedure.  After  exclusion
f non-signiﬁcant  and  non-explaining  variables,  the
esulting multivariable  regression  analysis  showed
hat obese  patients  had  a  non-signiﬁcantly  reduced
isk for  ICU  mortality  compared  with  non-obese
atients (adjusted  OR  0.53,  95%-CI  0.188—1.321,
 =  0.197)  as  displayed  in  Fig.  1.
This procedure  was  repeated  for  morbidity




Table  3  Subgroup  of  patients  with  vancomycin  therapy  an
non-obese  patients  (mean  ±  SD).
Variable  
Mean  vancomycin  trough  levels  in  mg/L
Fraction  of  vancomycin  trough  levels  below  10  mg/L
(%  of  measurements)
Fraction  of  vancomycin  trough  levels  above  20  mg/L
(%  of  measurements)
Achievement  of  reference  vancomycin  trough  level
(10—20  mg/L)  in  ﬁrst  TDM,  N  patients  (%)chanical ventilator support were included.
he  resulting  model  showed  a signiﬁcantly
ncreased  risk  for  obese  patients  for  invasive
entilator support  on  ICU  stay  with  an  adjusted
R of  1.841  (95%-CI  1.113—3.076,  p = 0.018,  see
ig.  2).
In a conﬁrmatory  analysis  using  the  technique
f propensity  score  matching,  the  cohort  was  re-
valuated.  The  resulting  1:1  matched  population
ncluded 260  patients.  In  130  obese  patients  alto-
ether 10  cases  died  compared  with  11  cases
ut of  130  non-obese  patients  (7.7%  versus  8.5%,
 =  0.902).  Morbidity  differed  signiﬁcantly  between
roups  in  the  matched  population  with  85  out  of
30 (65.4%)  obese  patients  requiring  mechanical
entilation compared  with  63  out  of  130  (48.5%)
on-obese patients  (p  =  0.008).  Duration  of  mechan-
cal ventilation  was  as  well  not  different  between
atched study  groups  [median  3  days  (1|9)  obese
ersus 3  (1|12)  non-obese  patients,  p  =  0.591]  in  this
nalysis paralleling  the  ﬁndings  of  the  univariate
nalysis.
d  results  of  therapeutic  drug  monitoring  for  obese  and
Non-obese
N  =  91
Obese  patients
N  =  26
p-Value
16.6  ±  7.8  18.2  ±  8.0  0.303
22 ±  32 27  ±  35  0.507
27 ±  33  39  ±  38  0.169
43 (47%)  6  (23%)  0.041
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Figure  1  Results  of  the  multivariable  regression  analysis  evaluating  all  cause  ICU  mortality  for  obese  compared  with
non-obese  patients.  OR  and  conﬁdence  intervals  are  displayed.
Figure  2  Results  of  the  multivariable  regression  analysis  evaluating  all  requirements  of  mechanical  ventilation  for
obese  compared  with  non-obese  patients.  OR  and  conﬁdence  intervals  are  displayed.




































































































ConclusionMI  is not  associated  with  increased  ICU  mortality  b
iscussion
he  most  important  ﬁnding  of  this  study  was  that
e did  not  ﬁnd  a  difference  between  obese  and
on-obese patients  regarding  ICU  mortality.  Distri-
ution of  infections  was  similar  but  signiﬁcantly
ore obese  patients  required  mechanical  venti-
ation.  Obese  patients  presented  more  frequently
ith relevant  comorbidities.  In  addition,  quality  of
ntibiotic  therapy  was  similar  between  groups  but
ifferences  in  vancomycin  serum  levels  suggest  that
osing is  more  complicated  in  obese  ICU  patients.
After evaluation  of  baseline  characteristics,
nticipated  differences  between  non-obese  and
bese patients  were  observed.  Obese  patients  pre-
ented signiﬁcantly  more  often  with  comorbidities
orresponding  to  the  trial  of  the  metabolic  syn-
rome with  cardiovascular  diseases  like  arterial
ypertension or  heart  insufﬁciency  and  diabetes
ellitus [25].  Consequently,  operative  admission
iagnoses were  different  with  more  obese  patients
eing  admitted  to  ICU  following  cardiac  surgery.
In our  dataset,  we  identiﬁed  a  higher  frequency
f postoperative  mechanical  ventilation  in  obese
atients,  a  circumstance  that  has  been  described
reviously [26,27].  Ventilator  support  has  been
dentiﬁed  as  one  major  risk  factor  for  development
f pneumonia  in  the  ICU  setting  [28]  and  pneumonia
tself inherits  an  attributable  mortality  of  about  10%
ue to  this  complication  [29]. Based  on  this,  it  could
e expected  that  more  obese  patients  are  observed
ith fatal  outcome  in  our  study.  In  contrast,  in
ur study  obese  patients  were  found  to  have  sim-
lar mortality  compared  with  non-obese  patients.
his phenomenon  has  already  been  described  as
besity paradox  [9].  As  all-cause  ICU  mortality  is
nﬂuenced  by  multiple  factors  or  imbalances  in
aseline  characteristics  we  carefully  evaluated  our
ata set  to  address  heterogeneity  between  groups.
ccordingly,  we  were  able  to  perform  a  propensity
core based  matching  procedure  to  optimize  homo-
eneity  of  the  resulting  subpopulation  concerning
aseline characteristics.  This  technique  was  used
o validate  the  multivariate  logistic  regression  anal-
ses and  ﬁnally,  no  difference  between  obese  and
on-obese  patients  was  found  in  regard  to  ICU  mor-
ality but  in  morbidity.  However,  it  should  be  noted
hat due  to  the  design  of  this  study  especially  unob-
erved  factors  may  interact  with  these  results.  As
xamples,  patients  exposure  to  antibiotics  outside
he observed  ICU  period  or  physical  state  of  patients
eﬂected in ASA  status  on  admission  may  interact
ith results.
Additionally,  we  scrutinized  quality  of  antibi-
tic therapy  in  the  study  population.  Antiinfective
anagement was  found  similar  between  groups
O
porbidity  583
hen  analysing  choice,  timing  and  duration  of
herapy  and  appropriate  infection  diagnostic.  In
ontrast,  obese  patients  where  at  higher  risk  for
nsufﬁcient  antibiotic  dosing  as  we  could  observe
igniﬁcantly less  obese  patients  with  sufﬁcient
erum levels  of  vancomycin  especially  after  induc-
ion of  therapy.  This  ﬁnding  is  in  concordance  with
he working  group  of  Thursky  et  al.  [21]. They
ecently reviewed  relevant  pharmacological  dif-
erences  between  obese  and  non-obese  patients
nd found  that  there  might  be  evidence  that  a
igher volume  of  distribution  and  relatively  higher
enal excretion  could  lead  to  altered  serum  levels
f antibiotics.  When  exemplarily  assessing  van-
omycin serum  levels  in  our  population,  indeed  we
ere able  to  identify  differences  in  initial  thera-
eutic drug  levels.  In  obese  patients  serum  trough
evels  after  initiation  of  vancomycin  therapy  were
ore often  out  of  targeted  range  and  had  to  be
dapted. In this  context  there  arises  the  question
hether dosing  for  other  important  antibiotics  in
ritically  ill  patients  are  sufﬁcient  if  they  are  not
ndividually  adapted  to  body  weight  [18,30].  Based
n these  ﬁndings  dosing  strategies  used  for  non-
bese  patients  should  be  transferred  with  caution
o the  obese  population.
imitations
his  study  evaluated  prospectively  obtained  data
nd included  a broad  patient  population  in  surgi-
al ICUs.  Principally,  for  this  study  design  there  is
n inherent  limitation  to  infer  on  causality  in  the
on-randomized  setting  but  we  carefully  evaluated
elevant baseline  characteristics  for  heterogeneity
nd used  powerful  statistical  technique  to  account
or imbalances.  Yet,  data  analysis  remains  limited
o observed  variables  and  there  are  many  further
ovariables that  may  be  of  interest  to  be  explored.
xemplarily, this  evaluation  is  limited  to  therapeu-
ic drug  monitoring  performed  regularly  to  achieve
ufﬁcient  number  of  observations  but  analysis  of
ther agents  was  not  possible  in  this  data  set.  Addi-
ionally, vancomycin  is  a hydrophilic  antibiotic  but
esults on  this  agent  cannot  simply  be  transferred
o other  antibiotics.  Also,  we  were  limited  in  regard
o sufﬁcient  data  evaluating  hepatic  or  renal  organ
unction  and  to  data  on  ICU  mortality  as  a  longer
ollow up  was  not  feasible  in  this  trial.bese  patients  differ  signiﬁcantly  from  non-obese












ventilation;  however,  mortality  is  similar  between
groups.  Especially  dosing  of  anti-infective  agents
like vancomycin  seems  to  be  more  complicated
in this  population.  When  available,  therapeutic
drug monitoring  may  support  optimizing  therapy  in
obese patients  and  recommendations  especially  in
the critical  ill  should  tailor  drug  dosing  also  based
on anthropometric  parameters.
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